Author: admin

HONG KONG, Feb. 27, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1,  a self-developed and differentiated HER3-targeting ADC (antibody-drug conjug

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: